| Business

Become a contributor

Bookmark Econotimes

| Business

TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans

SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off

Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge

Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning

Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks

Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing

Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised

FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns

TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment

Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch

Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links

Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies

Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million

Ford and Geely Explore Strategic Manufacturing Partnership in Europe

Washington Post Publisher Will Lewis Steps Down After Layoffs

Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit

Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings

©Econometrics LLC . All Rights Reserved.

Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference

Friday, February 9, 2018 1:00 PM UTC

YARDLEY, Pa., Feb. 09, 2018 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the Leerink Partners 7th Annual Global Healthcare Conference February 14, 2018, at 10:30 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event.

About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has corporate offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com.

Optinose Investor Contact
Jonathan Neely
[email protected]
267.521.0531

Optinose Media Contact
Kate Traynor, Sloane & Company
[email protected]
212.446.1871

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out

Netanyahu to Meet Trump in Washington as Iran Nuclear Talks Intensify

US Pushes Ukraine-Russia Peace Talks Before Summer Amid Escalating Attacks

Jack Lang Resigns as Head of Arab World Institute Amid Epstein Controversy

Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality

Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape

Antonio José Seguro Poised for Landslide Win in Portugal Presidential Runoff

Nicaragua Ends Visa-Free Entry for Cubans, Disrupting Key Migration Route to the U.S.

Bosnian Serb Presidential Rerun Confirms Victory for Dodik Ally Amid Allegations of Irregularities

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference

Editor's Picks

Welcome to EconoTimes